FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Saturday

 

Dice loaded for patients with late-stage MS, study shows





















In a new study, people with MS were given a dice-throwing task to determine their ability to assess risk. The results showed that the disease impairs decision-making ability as it progresses, especially in the late stages. Credit: topher76, shared under Creative Commons licence

People living with multiple sclerosis have the dice loaded against them when it comes to their decision-making ability as their neurological disease progresses, according to a new study from the University of Alberta's Faculty of Medicine & Dentistry.

"About half of people with MS will experience cognitive defects or limitations in that capacity. Decision-making becomes important to look at in these populations," says lead author Ashley Radomski, who completed the research as part of her master's thesis.

In the study, published in BMC Neurology, people with MS took part in an assessment that involves throwing dice, which has been shown in other studies to be a standard determinant of explicit risk.

The test, called the game of dice task, or GDT, challenges study participants to evaluate risks associated with throwing dice by choosing a combination of one, two, three or four digits as a predicted outcome of each roll. More numbers in a chosen combination means a less risky choice, but also means lower rewards for a correct guess—which, Radomski explains, can lure participants to make less advantageous choices that reveal their everyday decision-making capacity.

Esther Fujiwara, Radomski's supervisor and an associate professor in the Department of Psychiatry, helped develop the test as part of her own PhD studies. "People with MS are faced with many complex decisions on a regular basis—for example, choices about which medications to take or not take, what short- or long-term effects are desirable or undesirable, which side-effects seem acceptable or unacceptable, and so on," Fujiwara notes.

"What we found in our study is that those patients who have increased disease severity, as indicated by a particular subtype of MS or by greater structural changes in the brain, did have greater decision-making disabilities than patients who were considered less severe," Radomski says.

People with MS or their family members may find it helpful to keep a journal to help identify decision-making patterns over time. Radomski emphasizes that the journal should be discussed with the patient's primary physician or their neurologist for full assessment.

Radomski also notes that the rules of GDT were explained to participants at the beginning of the task, and remained consistent and on display throughout the rounds. GDT was administered as part of a two-hour standardized neuropsychological test battery to evaluate the participants' working and verbal memory, visual-spatial abilities and motor function, among other traits.

Story Source: The above story is based on materials provided by MEDICALXPRESS
Note: Materials may be edited for content and length

Labels:



Go to Newer News Go to Older News